Form 4: Harvard Bioscience CFO Jennifer Cote Reports Stock Transactions
SEC Form 4 Filing
Jennifer Cote, CFO of Harvard Bioscience, reports acquisition and disposal of company stock, including restricted stock units (RSUs) and shares withheld for tax obligations.
Summary
- Jennifer Cote, the Chief Financial Officer of Harvard Bioscience, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
- On March 5, 2024, she acquired 35,800 shares of common stock and 35,800 RSUs at $0.00.
- On March 6, 2024, 9,920 shares were withheld by the company at $4.11 to cover tax obligations upon the vesting of 29,880 RSUs.
- Following these transactions, Cote beneficially owns 168,738 shares of common stock, including RSUs with various vesting schedules and performance-based conditions.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not inherently convey positive or negative sentiment. It simply reports transactions in the company's stock by an insider.
Future Outlook
The document does not contain explicit forward-looking statements, but it outlines the vesting schedule and performance-based conditions of the RSUs, indicating future equity compensation for the CFO.
Industry Context
Form 4 filings are standard practice for company insiders and provide transparency into their transactions in the company's stock. This filing indicates the CFO's ongoing equity stake in Harvard Bioscience.
Comparison to Industry Standards
- Equity compensation through RSUs is a common practice among publicly traded companies to align management's interests with those of shareholders.
- Vesting schedules and performance-based conditions are typical features of RSU grants, designed to incentivize long-term performance and retention.
- Comparable companies in the life sciences and biotechnology sectors, such as Thermo Fisher Scientific or Agilent Technologies, also utilize equity compensation plans for their executives.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the CFO's equity ownership in the company.
- The vesting of RSUs incentivizes the CFO to contribute to the company's long-term success, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Acquisition of common stock and RSUs |
| 03/06/2024 | Shares withheld for tax obligations |
| 03/07/2024 | Date of Form 4 signature |
| 12/29/2024 | Vesting date for 17,928 RSUs (first installment) |
| 12/29/2024 | Vesting date for 11,171 RSUs |
| 03/19/2025 | First vesting installment of RSUs awarded on 03/05/2024 |
| 12/29/2025 | Vesting date for 17,928 RSUs (second installment) |
| 03/19/2026 | Second vesting installment of RSUs awarded on 03/05/2024 |
| 12/31/2026 | End of performance period for performance-based RSUs |
| 03/19/2027 | Third vesting installment of RSUs awarded on 03/05/2024 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.